Sanofi shakes up clin­i­cal plans for trio of pro­grams from De­nali, Prin­cip­ia and Kymab deals

Sanofi is shuf­fling its pipeline af­ter sev­er­al tri­al flops in an­ti-in­flam­ma­to­ry and can­cer drugs it land­ed through a part­ner­ship with De­nali and buy­outs of Prin­cip­ia and Kymab.

In its third-quar­ter re­port, Sanofi dis­closed it end­ed en­roll­ment in a study in­ves­ti­gat­ing alom­fil­imab, an an­ti-ICOS mAb that it got from its $1.5 bil­lion Kymab buy­out, for the treat­ment of sol­id tu­mors. The de­ci­sion was not based on any ob­served safe­ty sig­nal, the com­pa­ny added, though it didn’t pro­vide any more de­tails.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER